Whitehawk Therapeutics Inc (WHWK) is a Healthcare stock trading at $4.73 (as of 2026-08-21), with a market capitalization of $233.91M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Whitehawk Therapeutics Inc is a clinical-stage biopharmaceutical company that develops targeted treatments for cancers defined by specific genetic characteristics. Its work focuses on precision medicine approaches for these genetically characterized malignancies.
Understand Whitehawk Therapeutics Inc: how it makes money
Whitehawk Therapeutics develops precision biopharmaceutical therapies for genetically defined cancers, and its money is tied to both its clinical pipeline progress and reported product sales (including FYARRO).
EngineLine: As a clinical-stage precision oncology biopharma, Whitehawk’s route to profitability depends on moving patients and data through trials (like PRECISION1) and then scaling the impact of any resulting commercial product sales (such as FYARRO).
Business quality (Weak): Strong alignment between the business and measurable trial activity, but the company remains loss-making and largely dependent on clinical and commercialization milestones.
Bull case
Trial momentum is measurable in PRECISION1, with interim analysis participant count and planned full enrollment disclosed: PRECISION1 Interim Analysis Participant Count is 40, and PRECISION1 Planned Full Enrollment Participant Count is 120.
Reported patient benefit during the ongoing PRECISION1 trial supports the clinical readthrough thesis: Number of Patients in PRECISION1 Trial Still Benefiting is 25.
The company has an identifiable commercial line item, FYARRO sales revenue: FYARRO Sales Revenue is listed as an operating KPI (0.01 USD_B for the period shown).
Bear case
The company is not yet operating at an economic profit on an operating basis: Operating margin_pct is -213.0 for the period ending 2025-03-31.
A large portion of value is still tied to clinical outcomes, which may not translate into approvals or sales at scale: Multiple oncology trials are still in progress, including Phase 2 enrollment in endometrioid-type endometrial cancer and neuroendocrine tumors.
Operational focus on cost actions can signal financial pressure while trials continue: Research and Development Workforce Reduction is reported as 80 percent.